RTI-353

RTI-353 is a stimulant drug from the phenyltropane family. It is a selective DAT inhibitor, with negligible effects on the NET and SERT. RTI-353 was developed as part of a series of compounds related to RTI-31, but unlike most other phenyltropanes, it has a piperidine ring in place of the usual tropane ring.

Pharmacology

RTI-353 is a potent and selective inhibitor of the dopamine transporter, which is responsible for the reuptake of dopamine in the brain. By inhibiting this transporter, RTI-353 increases the amount of dopamine available in the brain, which can have stimulant effects. However, unlike many other stimulant drugs, RTI-353 does not significantly affect the norepinephrine transporter or the serotonin transporter, making it more selective for dopamine.

Development

RTI-353 was developed as part of a series of compounds related to RTI-31. These compounds were designed to be potent inhibitors of the dopamine transporter, with the goal of developing new treatments for conditions such as Parkinson's disease and attention deficit hyperactivity disorder (ADHD). However, unlike most other compounds in this series, RTI-353 has a piperidine ring in place of the usual tropane ring. This gives it a unique pharmacological profile, with a high selectivity for the dopamine transporter and negligible effects on the norepinephrine and serotonin transporters.

See also

• RTI-31
• Dopamine transporter
• Phenyltropane

References

<references/>

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

RTI-353

• 
  RTI-353 structure